title: Therapeutics: Silencing psoriasis.
authors.forename: James Mitchell
authors.initials: JM
authors.lastname: Crow
mesh_terms: D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000276:immunology; D010880:Piperidines; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D020381:Interleukin-17; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; D011993:Recombinant Fusion Proteins; D013792:Thalidomide; C479163:tofacitinib; D000077944:Alefacept; D000069549:Ustekinumab; C505730:apremilast